Evidence mapPaperPMID 40038239Full record

ReviewSignal transduction and targeted therapy2025

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Wenjing Xiao, Wenjie Jiang, Zheng Chen, Yu Huang, Junyi Mao, Wei Zheng, Yonghe Hu, Jianyou Shi

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. C-Terminal Nucleobase Modification Amplifies Peptide-Mediated Liposome Fusion.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Review

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenjing Xiao *Department of Pharmacy, The General Hospital of Western Theater Command, Chengdu, 610083, China.
Wenjie Jiang *Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Zheng Chen *School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.ORCID http://orcid.org/0009-0005-1555-7594
Yu Huang *School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
Junyi MaoSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Wei ZhengDepartment of Integrative Medicine, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
Yonghe HuSchool of Medicine, Southwest Jiaotong University, Chengdu, 610031, China.
Jianyou ShiDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. shijianyoude@126.com.ORCID http://orcid.org/0000-0002-1026-0282

Funding

Department of Science and Technology of Sichuan Province (Sichuan Provincial Department of Science and Technology) 2022JDTD0025National Natural Science Foundation of China (National Science Foundation of China) 82073311
6 · The paper itself

Abstract

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Indexed as

Drug Delivery SystemsDrug DevelopmentPeptidesVaccinesVaccines, SubunitHumansPeptidesVaccinesVaccines, Subunit

Identifiers

PMID40038239
PMCPMC11880366

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.